Pediatric-plan strategist must resolve whether to drop a secondary endpoint

Situation

505(b)(2) literature-to-product bridge table arrived with a pediatric ethicist objecting to the proposed design for pediatric-plan strategist. That is a Pharma & Life Sciences FDA Response and Labeling decision on to drop a secondary in an RWE group proposing a post-marketing study instead of a new RCT.

Decision

Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• Pediatric-plan strategist can defend Proceed under protocol from 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design in a Pharma & Life Sciences challenge.
• Pediatric-plan strategist cannot defend Proceed under protocol from 505(b)(2) literature-to-product bridge table; Pause the pathway is what the extract actually supports after a pediatric ethicist objecting to the proposed design.
• A pediatric ethicist objecting to the proposed design never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close to drop a secondary.
• Two facts in 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design conflict for pediatric-plan strategist; hold this FDA Response and Labeling file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against a pediatric ethicist objecting to the proposed design and write the one fact that would move to drop a secondary for pediatric-plan strategist.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design). The follow-on FDA Response and Labeling action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.